Orphazyme Teeters On The Brink As Arimoclomol File Is Pulled
NASDAQ Shares Delisted And Workforce Cut By 50%
All hopes for survival rest on a meeting with the US FDA about arimoclomol now that the Danish biotech has withdrawn its submission for the Niemann-Pick disease type C therapy with the European Medicines Agency.
